DTx Europe 2022

Edouard is the Co-Founder and CEO of Tilak Healthcare, a unique video game studio creating clinically validated medical mobile games to help monitor and rehabilitate patients affected by chronic diseases.

For more than 10 years, Edouard worked in the video game industry at Gameloft, a company developing and editing mobile video games, where he successively held the positions of Project manager in Paris, then Lead Producer in New Orleans and finally managing Director of Gameloft Madrid.

Driven by his passion for innovation and technology, he was also a writer for TechCrunch France, covering mobile apps, 2.0 web and entertainment topics.

Megan Coder, PharmD, MBA, is Chief Policy Officer of the Digital Therapeutics Alliance (DTA), an international non-profit trade association of industry leaders and stakeholders dedicated to improving clinical and health economic outcomes through the use of high quality, evidence-based digital therapeutics (DTx).

Megan founded DTA in 2017 and remains instrumental in developing the foundations for this quickly evolving industry. She leads DTA’s efforts related to thought leadership, global policy, international standard development, and the Alliance’s DTx Value Assessment & Integration Guide.

Trained as a pharmacist, Megan graduated from the University of Wisconsin—Madison and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association Foundation. Prior to DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

Kamal is an industry leader with 15+ years of experience in digital health from a provider perspective, most recently at MassGeneral Brigham, with a background in digital health strategy, product design and clinical research and validation. Kamal has developed and implemented 100+ digital health programs and is widely published in the value digital health can bring to healthcare delivery.

Sai has more than 20 years of experience across the pharmaceuticals, medical device and digital health business verticals. He has been intrapreneur at Aptar,building out the Connected Devices and Digital Health division. Prior to joining Aptar in 2017, Sai worked for 15 years at Allergan and Sanofi.

As the President of Aptar Digital Health, Sai is responsible for overall P&L responsibilities for the business. He has overseen acquisition of digital health companies (Voluntis and Cohero Health) as well as equity investments in various startups like Propeller Health, Sonmol (China) and Navia (India).

Featured on Forbes 30 Under 30, Vogue UK 10 Rising Female Stars 2018, Women of the Future UK Awards Finalist 2019 and TEDx Speaker. Named one of the “UK’s most influential people in digital and tech” in the 2021 BIMA 100 List.

Host of Royal Society of Medicine’s Digital Health Podcast, which has over 10,000 listens in 95+ countries. 68% of listeners are under the age of 35 years old, engaging the next generation of healthcare leaders.

Currently Head of Market Development at Leva Clinic, where we launched the UK’s first online chronic pain clinic. My role includes translating market need alongside a range of business development areas such as strategic partnerships. The company was selected as UK Department of International Trade’s 25 ‘One’s to Watch’ for Digital Health, and a finalist for Tech Nations Diversity and Inclusion Award 2021. Leva Clinic provides pain management services to the NHS and Boots UK customers.

Dr. John Krakauer leads all scientific discovery and validation for MindMaze following the acquisition in 2018 of the medtech company he founded called Neuro Motor Innovations.

In addition to serving as Chief Medical Advisor for MindMaze, John is also:

• John C. Malone Professor and Professor of Neurology, Neuroscience, and Physical Medicine and Rehabilitation at the Johns Hopkins University School of Medicine

• Co-director of the Brain, Learning, Animation, and Movement (BLAM) Lab

Whitney is a Director of Clinical Project Management. She oversees the implementation of multiple
clinical trials at Curebase, including some in digital therapeutics. She has worked in the decentralized
trial space for over 5 years and in clinical research for over 10.

Dr. Andrew Welchman, Executive Vice President for Impact at ieso, is a Neuroscientist, former Professor at the University of Cambridge, and highly published academic. He has extensive speaking experience which includes addressing the House of Lords. He is responsible for ensuring ieso sets, measures and meets its ambitious social and economic impact goals.

ieso is a multi-award winning provider of evidence-based talking therapy for mood and anxiety disorders. Now available to over 20 million people, ieso was one of the first organisations to successfully develop and deploy evidence-based mental telehealthcare at scale. Leveraging real-world clinical data, ieso has pioneered the application of technologies such as deep-learning and natural language processing to improve the quality and cost-effectiveness of mental healthcare delivery.

Recognising the global demand-supply gap in mental healthcare provision, ieso has recently commenced the clinical development of a range of AI-enabled digital assessment and therapeutic solutions that it hopes will complement and extend human care delivery around the world.

Kate is a Senior Principal in the EMEA Consulting team at IQVIA, currently based in
London. She has over 12 years of consulting experience, working with a broad range
of pharmaceutical, biotechnology, diagnostic, and digital health clients. Kate has
expertise in market access strategy, launch pricing, companion diagnostics and
access strategy in digital health. Kate holds a B.A. from Princeton University in
Molecular Biology

Jessica is Director of Digital Therapeutics at Vicore Pharma in Sweden. Previously, she led the European Policy work for the Digital Therapeutics Alliance and managed clinical projects for respiratory disease at Bellvitge Hospital in Barcelona. With 20 years’ experience in digital health – from developing virtual surgery devices to analysis of digital health frameworks at national level – she now develops digital therapeutics products for the US, European, and global markets.

Pierre has more than 20 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco.

In addition, Pierre is a Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.

Naveed is interested in how the brain controls movement in healthy and clinical human populations. Specifically, his research focuses on understanding the neural substrates that control upper-limb movements, and how these substrates reorganize following injury. He has experience in establishing and maintaining clinical research collaborations, both in North America (Johns Hopkins University, University of California Berkeley, University of Western Ontario) and across the world (University Hospital Zurich, University College London, St. Georges University). These research collaborations have allowed him to investigate upper-limb dysfunction in patients with a wide-variety of movement disorders (stroke, cervical spondylotic myelopathy, musicians’ dystonia, amputees, and callosal agenesis), in an effort to extract general principles of how the neural substrate that controls upper-limb function is organized. His work primarily involves the use of non-invasive, multi-modal experimental techniques (behavioural, fMRI, EMG, TMS). He holds an MSc. in computational biology from Cambridge University, a PhD. in brain-machine interfaces from Imperial College London, and post-doctoral research experience in University College London, Western University and Johns Hopkins School of Medicine.

Dr. Jin Lee is the Director of Digital Health at Astellas pharma. She most recently was the CEO and founder of a maternal/child startup. She was formerly at the innovation centers and venture arms of an American health insurance company and hospital systems, focused on $2-10MM digital health investments. Based in San Francisco, Dr. Lee advises multiple digital health startups and accelerator programs. Her passion is women’s health, children’s health, and social impact.

Susanne Gruber is VP Pharma Partnerships of Sidekick Health. As former Global Digital Health Solutions Head at Novartis Pharma, Susanne pioneered the wide-scale launch of a new Asthma drug together with a Digital Companion approved by EMA. She co-lead a cross-functional Global Program Team building a personalised, connected eco-system for Respiratory patients partnering with multiple digital health companies. Throughout her career at Novartis she had multiple commercial leadership roles across geographies. Before joining Novartis, she worked for Ernst & Young as Head eCommerce Enablement. Susanne holds a degree in Computer Science from Rosenheim Technical University of Applied Sciences.

Michael works as a Project & Key Account Manager for some of the
biggest German MedTech companies. In this role, he overlooks the
wide range of innovative IQVIA services from clinical research to
data analytics dedicated to MedTech. His former responsibilities
include different roles in research and consulting, most recently as a
manager of a university institute providing scientific services. With a
PhD in economics, he has been working on the topic of highly
competitive and regulated markets for many years. In this context,
one of his focus areas is the fast-growing market of digital health
applications and the implications of the German Digital Care Act.

Hélène Moore is a pharma executive with 20 years of experience in the life science industry. During her career, she has been involved in multiple aspects of drug development, partnering and commercialization. Since 2021, Hélène is the General Manager of Ethypharm Digital Therapy (EDT), a subsidiary of the European group Ethypharm. In her role, she is in charge of building a new type of company forging a unique corporate know-how that will enable EDT to lead the way to a pan-European commercial deployment for clinically-proven Dtx. Hélène Moore holds a degree in Biochemistry from the University of Montreal and an executive MBA from the University of Quebec in Montreal. She is also a Certified Corporate Director from INSEAD.

Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA over 20 years ago. In his current role as Chief Medical Solutions Officer, Matthias is responsible for leveraging GAIA’s decades of DTx medical research and expertise internationally and providing integrated solutions to payer and physician organizations.

Dr. Tim Ferris is the inaugural National Director of Transformation at NHS England and NHS Improvement and previously a Non-Executive Director on the Board. Tim was most recently CEO of the Mass General Physicians Organization (2017-2021) and was formerly the Senior Vice President for Population Health at Mass General Brigham overseeing performance for one of the largest accountable care organizations in the US. He founded the Center for Population Health, which reaches over one million patients annually, focusing on prevention and data to improve health, reduce inequities and save lives.

Tim trained in medicine and public health at Harvard University, and remains on the staff of Mass General. He was awarded numerous NIH and foundation grants and co-authored over 130 publications on health care quality measurement, health disparities and health IT.  Tim became a professor at Harvard Medical School in 2018 and continues as an adjunct Professor.

Dominick D. Kennerson, Global Head G4A, is a healthcare expert, with deep experience and insight
across several sectors, including public health, health innovation and entrepreneurship, healthcare
communications, and healthcare policy.
As Global Head of Bayer’s G4A (2020 – current), Dom supports one of the industry’s leading bio-
pharmaceutical platform approaches to digital health investments and partnerships, with a mission
to “change the experience of health”—putting people at the center of managing their health in the
digital age.

Quentin Le Masne is in charge of Development & Innovation for the Connected Health & Devices unit at Merck, focusing on smart devices, remote patient monitoring and digital companions to pharmaceutical treatments. Quentin worked in various positions in the field of medical devices, leading development teams with cross-functional expertise like software, electronic, mechanics, user experience to bring new products in the doctor’s and patient’s hands.

After a medical apprenticeship and studies in medical technology, I worked as a scientific
employee at the Federal Institute for Drugs and Medical Devices for more than seven years.
Among others, in the areas of approval of clinical trials with medical devices and vigilance.
The last two years were spent in the field of digital health applications (DiGA) as deputy
head of the according unit. In this area, I was intensively involved in the development of the
German DiGA fast-track and helped to design it. Since January 22, I have been in charge of
market access at Sympatient and now dedicate myself to solving the worldwide anxiety
crisis.

Marty is SVP Regulatory Innovation & Digital Medicine at EVERSANA, where he helps companies understand the dynamic landscape within digital medicine as they approach regulatory authorities and seek to commercialize their products.

He is a digital medicine and digital therapeutics veteran who has developed and launched innovative products targeting oncology, Alzheimer’s, autoimmune disease, and asthma via various regulatory and commercial pathways, has designed digital therapeutics clinical trials and commercial pilot studies, and has supported more than 50 companies over the past two years on regulatory strategy, regulatory submissions, policy, reimbursement, and commercial strategy.  As an indicator of his passion for innovation in digital medicine, he has been granted more than 10 breakthrough device designations by FDA for digital therapeutics and digitally-enabled medical devices.

David Boutellier is leading the European business at Kaia Health. He’s responsible for bringing Kaia’s digital therapies to market and increasing adoption with patients and doctors. He oversees medical affairs, market access, business development, sales and marketing.

David holds a an MSc in Innovation and Entrepreneurship from ESADE Barcelona and a MA in strategy and international management from University of St. Gallen. Previously to Kaia funded a digital health company in the pulmonary space. At Kaia he started with developing the COPD product and then built up the product management and UX design teams. Beginning of 2021 he switched to the commercial side to become Head of Europe.

Panos Papakonstantinou is a Digital Engagement Catalyst Leader with Roche. Panos has exceptional knowledge and expertise in digital transformation, agile ways of working, and a proven ability to coach, connect and inspire. Panos is leading the affiliate digital transformation acceleration, through orchestrating and connecting global opportunities with affiliates, evaluating specific digital customer engagement innovation, experimentation and scaling up innovation which can help achieve exceptional customer experience and ultimately deliver better outcomes for patients.

Prior to joining Roche, Panos was part of Novartis for more than 10 years holding multiple leadership roles in digital transformation. In the latest he led the conceptualization and development of a new digital therapeutic for patients, and prior he headed the Digital Commercial Region of Europe, reporting to the Chief Commercial Officer for Europe and leading a team to achieve impact focusing on digital commercial approach, brand strategy effectiveness and simplification.

He holds an international MBA and a Master’s degree in electrical and computer engineering. In recent years, Panos was a key contributor to several whitepaper publications about marketing in the pharmaceutical industry, and gave several keynotes at international conferences focusing on Digital.

Julian is Co-Founder and Chief Product Officer at Sympatient and responsible for the digital therapeutics along the patient journey for anxiety disorders. He began his career as a clinical psychologist and researcher at the University of Luebeck. From his combined interests in high-tech and clinical research for third-wave and digital treatment methods he developed the idea for supercharged human care in the space of anxiety disorders and founded Sympatient in 2017 with his co-founders.

Dr Reddy trained in Paediatrics in various hospitals and community settings in England before taking up a post as a Consultant Paediatrician in Peterborough in 2001. He has specialist clinical expertise in neurodevelopmental disorders (Autism, ADHD and Learning Disability), physical disability, safeguarding children and Special Educational Needs. 

His research interests include Autism and use of digital health solutions in neurodevelopmental disorders. His other interests include medical leadership, large scale change management in the NHS, user involvement and medical informatics.

He has previously fulfilled several roles including National Clinical Lead (Children and Young People) for the NHS Institute for Innovation and Improvement, Clinical Director, Designated Doctor for Safeguarding Children, Medical Advisor for Adoption and Fostering and Designated Medical Officer for Special Educational Needs.

He is a member of NHS Digital Academy Cohort 3 Digital health Leadership program. He has completed PG Diploma in Digital Health Leadership at Imperial College and enrolled to do Masters in Digital Health Leadership.

As Head of Happify Health’s Pharma Specialty Solutions/Corporate Strategy, Chris is leading the effort to bring Happify’s platform to the pharmaceutical and healthcare industry. Recently he served as a Board Member of the Digital Therapeutic Alliance (DTA). In addition, he was a professor at the University of Utah and served as Executive Director of the Sorenson Center for Discovery & Innovation, a digital therapeutic game incubator. He is the co-author of two books on innovation, creativity, and leadership: Tension – The Energy of Innovation; and Solving for Why – Change Your Identity, Change Your Future. He is the named inventor on 12 issued patents, has been a founding leader in 10 startups, and has held leadership positions at JP Morgan and PwC. He holds a doctorate from George Washington University in Human and Organizational Learning, and an M.B.A. from UCLA Anderson School.

Beth Wolff is the Chief Commercial Officer at Brain+, a Copenhagen based digital therapeutics company developing treatments for dementia and Alzheimer’s Disease. Prior to joining Brain+, Beth held various leadership positions at Novo Nordisk, Sandoz, and LEO Pharma, in the areas of Commercial Intelligence and Excellence. Beth is driven by the belief that healthcare can be made more efficient and accessible through digital tools and is excited by the opportunities for care and disease management that digital is enabling. She is a passionate advocate for the needs of people with dementia and sees a great future of new and better care through digitalization.

Dr Rayna Patel is a medical doctor & neuroscientist with an MPhil in Translational Medicine. She has extensive experience in academia (Cambridge, Harvard, MIT, Columbia) and was an Associate Fellow of Clare Hall College, Cambridge. Rayna has subsequently held strategic & commercial roles in government policy, tech startups & the Cabinet Office’s Nudge Unit, where she used behavioural science to rewire patient behaviours through digital products.
She is currently CEO and Co-Founder of Vinehealth, a digital platform using a combination of behavioural science and AI to improve the quality of life and survival of cancer patients, whilst generating crucial real-world data to better inform healthcare delivery and drug development.

As co-founder and managing director Christian is in charge of sales, market access, and reimbursement for Sympatient – the first digital anxiety clinic. He has a strong passion for solving complex problems in healthcare systems to ultimately enable better access to care for patients. Christian holds a degree in economics from Jacobs University, an MPhil from the University of Cambridge, and has been a visiting student at Harvard University.

Nora Blum is the CEO and founder of Selfapy. She studied psychology at the University of Cambridge and went through various work stations in the clinical field (e.g. clinic and polyclinic for psychiatry and psychotherapy at the University Hospital Hamburg-Eppendorf). She then switched to the field of economy and worked for Rocket Internet in business development. While studying, she developed the desire to help people who suffer from mental health issues with a solution accessible to everyone. In early 2016 she founded Selfapy together with Katrin Bermbach.

John has a dual degree in Psychology and Economics, and is the co-founder and CEO of Alex Therapeutics – a company developing smart standalone digital therapeutics for addiction and mental health.